DHEA bill returns
This article was originally published in The Tan Sheet
Sen. Chuck Grassley, R-Iowa, on March 5 reintroduces a bill to list dehydroepiandrosterone as an anabolic steroid under the Controlled Substances Act. Co-sponsored by Sens. Dick Durbin, D-Ill. and John McCain, R-Ariz., S. 762 has been referred to the Judiciary Committee. In a same day release, Grassley says DHEA has "a number of potential long-term physical and psychological effects" including heart disease, cancer, stroke and liver damage. Industry groups maintain DHEA has little to no potential for abuse. Grassley previously introduced the measure in 2005 (1"The Tan Sheet" June 6, 2005, p. 11)...
You may also be interested in...
A new bill sponsored by Sen. Charles Grassley (R-Iowa) would regulate dehydroepiandrosterone (DHEA) as an anabolic steroid under the Controlled Substances Act
France plans to begin issuing manufacturing quality certificates so firms can import ordinary cosmetics into China without animal testing under a 2020 draft regulation. The Personal Care Products Council is working to find a comparable solution for US manufacturers.
The calcineurin inhibitor, only the second drug to be approved by the US FDA for lupus nephritis, will be competing against GlaxoSmithKline’s Benlysta.